NEW YORK, Jan. 3, 2019 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE American:
ATNM) announced today that Sandesh
Seth, Actinium's Chairman and Chief Executive Officer will
present at the Biotech Showcase™ 2019 being held on January 7-9. The conference will be held at the
Hilton San Francisco Union Square. Details of Actinium's
presentation are as follows:
Date: Monday, January 7, 2019
Time: 10:00 AM PT
Track: Yosemite A (Ballroom Level)
Venue: Hilton San Francisco Union Square
Members of Actinium's Executive and Corporate Development teams
will be available for 1-on-1 meetings during the conference. Those
interested in scheduling a meeting with Actinium may do so by
contacting Steve O'Loughlin,
Actinium's Principal Financial Officer via email to
soloughlin@actiniumpharma.com.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an
investor and networking conference devoted to providing private and
public biotechnology and life sciences companies with an
opportunity to present to, and meet with, investors and executives
in one place during the course of one of the industry's largest
annual healthcare investor conferences, J.P. Morgan Annual
Healthcare Conference.
About Actinium Pharmaceuticals, Inc.
Actinium
Pharmaceuticals Inc. is focused on improving patient access and
outcomes to cellular therapies such as bone marrow transplant (BMT)
and CAR-T with its proprietary, chemotherapy free or sparing,
targeted conditioning technology. Actinium is the only company with
a multi-disease, multi-target, drug development pipeline focused on
targeted conditioning. Its targeted conditioning technology is
enabled by ARC's or Antibody Radiation Conjugates that combine the
targeting ability of monoclonal antibodies with the cell killing
ability of radioisotopes. Actinium's pipeline of clinical-stage
targeted conditioning ARCs target the antigens CD45 and CD33 for
patients with a broad range of hematologic malignancies including
acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and
multiple myeloma (MM), acute lymphoblastic leukemia (ALL),
Hodgkin's lymphoma and Non-Hodgkin's lymphoma. Actinium's Iomab-ACT
program is designed to be a universal lymphodepletion technology
intended to eliminate the need for chemotherapy-based conditioning
prior to CAR-T or other adoptive cellular therapies.
Iomab-B, Actinium's lead targeted conditioning product
candidate, is currently enrolling patients in the pivotal Phase 3
SIERRA trial in patients age 55 or older, with active, relapsed or
refractory AML. Iodine-131-apamistamab (Iomab-B), combines the
anti-CD45 monoclonal antibody labeled with iodine-131 for
myeloablation prior to a bone marrow transplant. CD45 is expressed
on leukemia, lymphoma and normal immune cells. Iomab-B has been
studied in over 500 patients in 10 clinical trials in numerous
hematologic diseases. Actinium's Iomab-ACT program is an expansion
of its CD45 program that is intended to be a universal,
chemotherapy-free solution for targeted lymphodepletion prior to
CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is
expected to improve CAR-T cell expansion, reduce CAR-T related
toxicities and expand patient access to CAR-T treatment and
potentially other adoptive cell therapies. Due to its lower payload
dose, lymphodepletion with the Iomab-ACT program can be
accomplished through a single outpatient infusion. Actinium intends
to advance its Iomab-ACT program with CAR-T focused collaborators
from academia and industry.
Actinium's pipeline also includes a potentially best-in-class
CD33 program with its ARC comprised of the anti-CD33 antibody
lintuzumab labeled with the alpha-particle emitter actinium-225.
Its CD33 program is currently being studied in multiple clinical
trials for targeting conditioning and as a therapeutic in multiple
diseases and indications including AML, MDS and MM. Actinium
applies its CD33 program at high doses to target CD33+ cells of the
myeloid lineage in combination with reduced intensity conditioning
(RIC), which together are intended to result in myeloablative
outcomes with a more benign and well tolerated profile than high
intensity chemotherapy myeloablation. Actinium is focused on
applying its CD33 program at low doses in combination with other
therapeutic modalities including chemotherapy, targeted agents and
immunotherapies.
Actinium is also developing its proprietary AWE or Antibody
Warhead Enabling technology platform which utilizes radioisotopes
including iodine-131 and the highly differentiated actinium-225
coupled with antibodies to target a variety of antigens that are
expressed in hematological and solid tumor cancers. The AWE
technology enables Actinium's internal pipeline and with the
radioisotope Actinium-225 is being utilized in a collaborative
research partnership with Astellas Pharma, Inc. Actinium's clinical
programs and AWE technology platform are covered by a portfolio of
75 patents covering composition of matter, formulations, methods of
use and also methods of manufacturing the radioisotope Actinium-225
in a cyclotron.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-the-2019-biotech-showcase-in-san-francisco-300772157.html
SOURCE Actinium Pharmaceuticals, Inc.